These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

944 related articles for article (PubMed ID: 33663735)

  • 41. Harnessing RNA Interference for Cholesterol Lowering: The Bench-to-Bedside Story of Inclisiran.
    Wilkinson MJ; Bajaj A; Brousseau ME; Taub PR
    J Am Heart Assoc; 2024 Mar; 13(6):e032031. PubMed ID: 38456415
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inclisiran, the billion-dollar drug, to lower LDL cholesterol - is it worth it?
    Doggrell SA
    Expert Opin Pharmacother; 2020 Nov; 21(16):1971-1974. PubMed ID: 32749892
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inclisiran in patients with prior myocardial infarction: A post hoc pooled analysis of the ORION-10 and ORION-11 Phase 3 randomised trials.
    Landmesser U; Koenig W; Leiter LA; Raal FJ; Ray KK; Wright RS; Han J; Conde LG; Schwartz GG
    Atherosclerosis; 2023 Dec; 386():117354. PubMed ID: 38016401
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial.
    Blom DJ; Harada-Shiba M; Rubba P; Gaudet D; Kastelein JJP; Charng MJ; Pordy R; Donahue S; Ali S; Dong Y; Khilla N; Banerjee P; Baccara-Dinet M; Rosenson RS
    J Am Coll Cardiol; 2020 Jul; 76(2):131-142. PubMed ID: 32646561
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis.
    Desai NR; Campbell C; Electricwala B; Petrou M; Trueman D; Woodcock F; Cristino J
    Am J Cardiovasc Drugs; 2022 Sep; 22(5):545-556. PubMed ID: 35595929
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2).
    Chai M; He Y; Zhao W; Han X; Zhao G; Ma X; Qiao P; Shi D; Liu Y; Han W; An P; Li H; Yan S; Ma Q; Deng H; Qian L; Zhou Y;
    BMC Med; 2023 Feb; 21(1):77. PubMed ID: 36855099
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Small interfering ribonucleic acid for cholesterol lowering - Inclisiran: Inclisiran for cholesterol lowering.
    Soffer D; Stoekenbroek R; Plakogiannis R
    J Clin Lipidol; 2022; 16(5):574-582. PubMed ID: 35909047
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An "Inclisiran First" Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease.
    Koren MJ; Rodriguez F; East C; Toth PP; Watwe V; Abbas CA; Sarwat S; Kleeman K; Kumar B; Ali Y; Jaffrani N
    J Am Coll Cardiol; 2024 May; 83(20):1939-1952. PubMed ID: 38593947
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia.
    Menzin J; Aggarwal J; Boatman B; Yu J; Stern K; Harrison DJ; Patel JG
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1270-1276. PubMed ID: 29172973
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.
    Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R
    Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center.
    Shah P; Glueck CJ; Jetty V; Goldenberg N; Rothschild M; Riaz R; Duhon G; Wang P
    Lipids Health Dis; 2016 Aug; 15(1):132. PubMed ID: 27538393
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study.
    Boccara F; Kumar PN; Caramelli B; Calmy A; López JAG; Bray S; Cyrille M; Rosenson RS;
    J Am Coll Cardiol; 2020 May; 75(20):2570-2584. PubMed ID: 32234462
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Subclinical coronary atherosclerosis and cardiovascular risk stratification in heterozygous familial hypercholesterolemia patients undergoing statin treatment.
    Miname MH; Bittencourt MS; Nasir K; Santos RD
    Curr Opin Lipidol; 2019 Apr; 30(2):82-87. PubMed ID: 30649025
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia.
    Kastelein JJ; Hovingh GK; Langslet G; Baccara-Dinet MT; Gipe DA; Chaudhari U; Zhao J; Minini P; Farnier M
    J Clin Lipidol; 2017; 11(1):195-203.e4. PubMed ID: 28391886
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategies.
    Brandts J; Ray KK
    Curr Opin Lipidol; 2020 Aug; 31(4):182-186. PubMed ID: 32487819
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies.
    Wright RS; Collins MG; Stoekenbroek RM; Robson R; Wijngaard PLJ; Landmesser U; Leiter LA; Kastelein JJP; Ray KK; Kallend D
    Mayo Clin Proc; 2020 Jan; 95(1):77-89. PubMed ID: 31630870
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inclisiran adjuvant therapy to statins for the use of hypercholesterolemia: a commentary.
    Vohra LI; Rizwan K; Saeed E; Hamza MSA; Ochani S
    Egypt Heart J; 2023 Jul; 75(1):60. PubMed ID: 37439881
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inclisiran: Small Interfering Ribonucleic Acid Injectable for the Treatment of Hyperlipidemia.
    Hughes-Hubley F; Iskander M; Cheng-Lai A; Frishman WH; Nawarskas J
    Cardiol Rev; 2022 Jul-Aug 01; 30(4):214-219. PubMed ID: 35666780
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
    Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
    J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a).
    Katsiki N; Vrablik M; Banach M; Gouni-Berthold I
    Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 48.